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This special issue was focused on the role and the eﬀects
of glucagon-like peptide-1 (GLP-1) in type 2 diabetes.
This gastrointestinal hormone, which is mainly secreted
after meals, enhances glucose-stimulated insulin release and
inhibits food intake. The response of circulating active
G L P - 1c o n c e n t r a t i o n sa f t e ras t a n d a r dm e a l ,a sw e l la sa f t e r
an oral glucose load, has been reported to be reduced in
type 2 diabetic patients in comparison with healthy subjects.
Available data suggest that GLP-1 plays a relevant role in the
regulationofpostprandialglucosemetabolisminphysiologic
conditions.Furthermore,theimpairmentofGLP-1secretion
after meals could contribute to the pathogenesis of hyper-
glycemia in type 2 diabetes. Several new drugs act through
the GLP-1 signaling system to stimulate insulin release and
regulate blood glucose levels in patients with diabetes.
This special issue includes 8 articles: three mechanistic
studies and ﬁve reviews and meta-analyses, exploring the
putative favourable eﬀects of the incretins on beta-cell
function and mass and on gastrointestinal motor function.
The reviews and meta-analyses are focused on the promising
beneﬁcial extraglycaemic eﬀects of the incretin-based ther-
apy, including those on central nervous system (cognitive
impairment) and cardiovascular risk. Last but not least,
an interesting and intriguing review on gene therapy using
expression vectors of GLP-1 and other incretin mimetics
in the salivary gland for the treatment of type 2 diabetes
mellitus (T2 DM) is presented.
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